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Abstract
The recent 21st Century Cures Act propagates innovations to accelerate the dis-
covery, development, and delivery of 21st century cures. It includes the broader
application of Bayesian statistics and the use of evidence from clinical expertise. An
example of the latter is the use of trial-external (or historical) data, which promises
more efficient or ethical trial designs. We propose a Bayesian meta-analytic approach
to leveraging historical data for time-to-event endpoints, which are common in oncol-
ogy and cardiovascular diseases. The approach is based on a robust hierarchical
model for piecewise exponential data. It allows for various degrees of between trial-
heterogeneity and for leveraging individual as well as aggregate data. An ovarian
carcinoma trial and a non-small-cell cancer trial illustrate methodological and prac-
tical aspects of leveraging historical data for the analysis and design of time-to-event
trials.
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1 INTRODUCTION
Historical data often provide valuable information for the design of a new study. For example, sample size calculations depend on
variability and effect sizes from previous trials. However, current practice usually ignores historical data in the analysis of a new
trial. In recent years, however, leveraging historical data in the analysis of clinical trials has been encouraged by the European
Medicines Evaluation Agency (EMEA)? , the US Food and Drug Administration (FDA) including the Prescription Drug User
Fee Act VI? , and the 21st Century Cures Act? . Recent examples in various phases of drug and medical device development
include French et al.? , Hueber et al.? , and Campbell? .
Leveraging historical data is appealing to practitioners and regulators for reasons of improved efficiency (smaller and therefore
faster trials) and ethics (fewer patients assigned to a less effective treatment). Yet this may be challenging and requires care. First,
identifying relevant historical data requires good judgment and collaboration by the various stakeholders of a clinical trial. A
thorough review of the literature and other resources (e.g. registry data) in a specific disease (e.g., study population, definition
of endpoint, data collection etc.) is important. This is ideally done using systematic reviews techniques (Egger et al.? , Cochrane
Collaboration? , Rietbergen et al.? ), and involving a third party or independent group may be useful.
Second, a principled statistical approach, which leverages the historical data while allowing for potential differences between
historical and actual data, is needed. Various statistical methods have been proposed in this context: Pocock’s bias model? ,
power priors (Ibrahim and Chen? ), commensurate priors (Hobbs et al.? ), and meta-analytic-predictive priors (Spiegelhalter et
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al.? , Neuenschwander et al.? , Schmidli et al.? ); for an overview, see Viele et al.? and Lewis et al.? . They are very similar and
use hierarchical models that allow for different parameters in the historical and actual trial, which will imply discounting of the
historical data when analyzing the new trial.
Here, we will be concerned with leveraging historical control data for time-to-event endpoints (e.g., time to disease progres-
sion, time to death). Such endpoints are the primary outcome in various therapeutic areas, including oncology and cardiovascular
diseases. Among the various methods we will use the meta-analytic-predictive (MAP) approach. This is essentially a Bayesian
random-effects meta-analysis of the historical data with the prediction of the parameter in the new trial. The basic model, which
assumes exchangeable parameters for the new and the historical trials, can be extended in various ways. We will extend theMAP
methodology for one-dimensional parameters to piecewise exponential (PWE) time-to-event data. To hedge against potential
prior-data conflict, we propose an extension of the basic exchangeability assumption by adding a robust mixture component.
Although using historical data in clinical trials has gained increasing interest recently, applications in the time-to-event setting
are sparse. A major challenge is the need of patient-level data for most of the statistical time-to-event approaches (Murray et
al.? , Bertsche et al.? , and Hobbs et al. 2013? ). Our proposed methodology is applicable for both patient-level and summary
data (e.g. Kaplan Meier curves), the latter often being available from publications.
The paper is structured as follows. In Section 2 we introduce the basicMAPmethodology and extend it to time-to-event data.
Two applications are discussed in Section 3, with emphasis on the analysis of trial data in the presence of historical data, and
the design of a new trial leveraging historical data, respectively. Section 4 concludes with a discussion.
2 METHODS
In this section we discuss a meta-analytic-predictive (MAP) approach to leveraging historical data for a time-to-event outcome.
We consider the randomized setting, with a control and test treatment for which the use of historical data is confined to the
control group. That is, while the prior distribution for the control (baseline) hazard will be informed by historical data, the prior
for the treatment contrast (proportional hazards parameter) will be weakly informative.
2.1 The meta-analytic-predictive (MAP) prior distribution
The MAP approach uses the historical control data from 퐽 trials 푌1,… , 푌퐽 to obtain the MAP prior distribution for the control
parameter 휃⋆ in the new study
푝(휃⋆|푌1,… , 푌퐽 ) (1)
The derivation of (1) is meta-analytic, using a hierarchical model with trial-specific parameters 휃⋆, 휃1,… , 휃퐽 . The simplest
hierarchical model assumes exchangeable parameters across trials, which is usually represented as
휃푗 = 휇 + 휖푗 , 휖푗 ∼ 푁(0, 휏2), 푗 = ⋆, 1,… , 퐽 (2)
While (2) allows for biases, they are assumed non-systematic. If needed, the basic model can be extended by replacing 휇 by푋푗훽
to allow for systematic biases explained by covariates trial-specific covariates 푋푗 .
2.2 A hierarchical model for piecewise exponential time-to-event data
We assume piecewise exponential data and the time axis partitioned into 퐾 intervals,
(퐼푘−1, 퐼푘], 푘 = 1, ..., 퐾, 퐼0 = 0 (3)
For each historical trial and time interval, there are 푛푗푘 control patients at risk (with a corresponding total exposure time 퐸푗푘),
of which 푟푗푘 experience an event. For each interval, the data model is Poisson
푟푗푘|휆푗푘 ∼ Poisson(휆푗푘퐸푗푘), 푗 = 1,… , 퐽 ; 푘 = 1,… , 퐾 (4)
where 휆푗푘 is the hazard in interval 푘 of trial 푗. Of interest is the prior for the control hazards 휆⋆1,… , 휆⋆퐾 in the new trial. The
similarity of the new and the historical trials is captured in a parameter model. The simplest model assumes normally distributed
log-hazard parameters 휃푗푘 = log(휆푗푘),
휃⋆푘, 휃1푘,… , 휃퐽푘|휇푘, 휏푘 ∼ 푁(휇푘, 휏2푘), 푘 = 1,… , 퐾 (5)
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For the across-trial mean parameters 휇푘, different implementations are possible. First, ignoring the time structure, the parameters
may be assumed unrelated, with independent prior distributions
휇푘 ∼ 푁(푚휇푘, 푠2휇푘), 푘 = 1,… , 퐾 (6)
Second, the time structure of 휇1,… , 휇퐾 may bemodelled using, for example, a multivariate normal distribution with a structured
covariance matrix (e.g. AR(1)), or a dynamic linear model
휇푘 ∼ 푁(휂푘, 휎2푘), 푘 = 1,… , 퐾 (7)
휂푘 = 휂푘−1 + 휌푘−1 푘 = 2,… , 퐾 (8)
The latter will be used in the applications of Section 3, which gives more details for the prior distributions.
Finally, prior distribution for the across-trial standard deviations 휏푘 on the log-hazard scale are required. We will use half-
normal priors
휏푘 ∼ half-normal(푠휏푘) (9)
with scale parameter 푠휏푘 representing anticipated heterogeneity. A weakly-informative half-Normal prior with 푠휏푘=0.5 puts
approximately 5% probability for values of 휏푘 greater than 1. This allows small to large between trial heterogeneity. As for the
mean parameters 휇푘, rather than assuming unrelated 휏푘 parameters, a multivariate normal distribution or dynamic linear model
could be used for the log(휏) parameters.
From the above data model, parameter model, and prior distributions, the MAP prior for the vector of log-hazards in control
group then follows as the conditional distribution of 휃⋆1 ,… , 휃⋆퐾 given historical data,
푝(휃⋆1 … , 휃⋆퐾 |푟, 퐸) (10)
where 푟 and 퐸 denote the number of events and exposure times across all historical trials and time intervals. TheMAP prior can
be obtained via MCMC. WinBUGS/JAGS code is given in the Appendix B.
2.3 Prior effective number of events
When desiging a new trial, knowing the amount of information introduced by theMAP prior is useful. It is sometimes expressed
as the prior effective sample size (ESS), or, in the time-to-event setting, the effective number of events (ENE). Various methods
have been suggested (Malec? , Morita et al.? , Neuenschwander et al.? , Pennello and Thompson? ). They compare the informa-
tion of the prior (variance or precision) to the one from one observation (or event). While conceptually similar, they can lead to
suprisingly different ESS or ENE.
We will use an improvement, the expected local-information-ratio 퐸푆푆퐸퐿퐼푅 as introduced by Neuenschwander et al.? . It is
defined as the expected (under the prior) ratio of prior information 푖(푝(휃)) to Fisher information 푖퐹 (휃)
퐸푆푆퐸퐿퐼푅 = 퐸휃
{
푖(푝(휃))
푖퐹 (휃)
}
(11)
where 푖(푝(휃)) = −푑2 log 푝(휃)∕푑휃2 and 푖퐹 (휃) = −퐸푌1|휃{푑2 log 푝(푌1|휃)∕푑휃2}.It can be shown that, like the other methods, 퐸푆푆퐸퐿퐼푅 fulfills the necessary condition of being consistent with the well-
knownESS for conjugate one-parameter exponential families. Unlike previousmethods, however, it also fulfills a basic predictive
criterion. That is, for a sample of size 푁 , the expected posterior ESS (under the prior distribution) is the sum of the prior ESS
and푁 .
For the piecewise exponential model with log-hazard parameters 휃⋆푘 (푘 = 1,… , 퐾) in the new trial, the Fisher information
푖퐹 (휃⋆푘) for one event is 1. Since theMAP priors for the log-hazard parameters are available only as an MCMC sample, approx-
imations for 푝(휃⋆푘) will be needed. Mixtures of standard distributions are convenient and can approximate these distributions
with any degree of accuracy (Dalal and Hall? , Diaconis and Ylvisaker? ). Fitting mixture distributions can be done by various
procedures (e.g., SAS? , R package RBesT? ,? ). Finally, after having obtained the effective number of events for each log-hazard
parameter, the total effective number of events of theMAP prior follows as 퐸푁퐸 = ∑퐾푘=1 퐸푆푆퐸퐿퐼푅(휃⋆푘).
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2.4 Analysis of the data in the new trial
We now turn to the analysis of the new, randomized trial, where the control treatment (퐶) will be compared to a test treatment
(푇 ). For the piecewise exponential model, the control and treatment data in interval 푘 follow Poisson distributions
푟퐶⋆푘|휆퐶⋆푘 ∼ Poisson(휆⋆푘퐸퐶⋆푘), 푟푇⋆푘|휆푇⋆푘 ∼ Poisson(훽휆⋆푘퐸푇⋆푘) (12)
where 휆⋆푘 = exp(휃⋆푘) are the control hazards, and 훽 is the Cox proportional hazards parameter. Prior information for the control
log-hazards 휃⋆푘 are given by the MAP prior (10), whereas the prior for 훽 will usually be weakly-informative.
When leveraging historical data, the analysis for the new trial can be done in two ways.
• Following the MAP approach, one would combine the MAP prior (10) from historical controls with the likelihood of the
new data (12). This is complicated because the MAP prior for the 퐾 control log-hazards 휃⋆ is not known analytically
but only available as an MCMC sample. Approximations of the MAP prior could be used; for example, by matching a
multivariate normal distribution with the same means, standard deviations, and correlations; or, mixture approximations
to the MAP priors could be used. The latter would allow for accurate approximations but would also be technically more
complex.
• Alternatively, the meta-analytic-combined (MAC) approach can be used. It consists of the hierarchical analysis of all the
data and has been shown to be equivalent (Schmidli et al.? ) to theMAP approach. Importantly, it is computationally easier
than the two-step MAP approach and is therefore used here. For applications and respective code, see Section 3 and the
Appendix, respectively.
2.5 Robust meta-analyses
To address the possibility of prior-data conflict, Schmidli et al.? proposed robust versions of MAP or MAC analyses. The idea
builds on exending the standard parameter model (exchangeable parameters), allowing the control parameter in the new trial to
be non-exchangeable with the historical parameters. The implementation uses a mixture distribution with weights 푤 and 1 −푤
for exchangeability and non-exchangeablity, respectively.
This idea can be easily extended to the time-to-event setting as follows: for each interval 푘 the robust version assumes
exchangeablity, 휃⋆푘 ∼ 푁(휇푘, 휏2푘), with probability 푤푘 and non-exchangeability with probability 1 − 푤푘. For the latter,interval-specific prior distributions
휃⋆푘 ∼ 푁(푚휃푘, 푠2휃푘) (13)
are needed. To achieve good robustness, weakly-informative priors should be used (for example, approximate unit-information
priors, i.e., 푠푘 = 1 for exponential data on the log-scale). Of note, even though the 푤푘 are fixed, the Bayesian calculus ensures
dynamic updating. That is, the prior weights푤푘 will be updated to posterior weights depending on the similarity of the new and
historical data. Eventually on may be interested in extending this idea to all trials by introducing trial-specific mixture weights
푤푗푘, 푗 = 1,… , 퐽 , 푘 = 1,… , 퐾 .
3 APPLICATION
We now discuss two applications of leveraging historical time-to-event data. The first illustrates the joint analysis of historical
and new data with the meta-analytic-combined approach of Section 2.4, whereas the second emphasizes the design of a new
trial in the presence of historical data.
3.1 Analysis with historical data
Voest et al.? and Fiocco et al.? investigated survival data from ten studies on patients with advanced epithelial ovarian carci-
noma. For our purpose, we assume the last study in Table 1 as the study of interest and the data of the remaining nine studies as
the historical data. Thus, we want to infer the survival curve of the last study while leveraging the data from the other studies.
The Kaplan-Meier plots in Figure 1 show considerable heterogeneity across the nine historical trials (left panel), with median
survivals ranging from 1 to 2.9 years.
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Fiocco et al.? used the following 12 invervals (in years): [0-0.25], (0.25-0.50], (0.50-0.75], (0.75-1], (1-1.25], (1.25-1.50],
(1.50-1.75], (1.75- 2.08], (2.08-2.50], (2.50-2.92], (2.92-3.33], and (3.33-4]. For the following meta-analytic analyses, the num-
ber of deaths and total exposure time per interval have been extracted from the published Kaplan-Meier plots using the Parmar
et al.? approach: the total exposure time (퐸푗푘) for interval (퐼푘−1, 퐼푘] and trial 푗 is calculated as
퐸푗푘 =
퐿푗푘
2
× (푟푗푘 + 푐푗푘) + 퐿푗푘 × (푛푗푘 − 푟푗푘 − 푐푗푘); 푗 = 1,… , 10, 푘 = 1,… , 12
Here, 퐿푗푘 is the interval length, and 푛푗푘, 푟푗푘 and 푐푗푘 are the number of patients at risk, dead, and censored, respectively. The data
extraction assumes constant censoring rates for each interval and all deaths at mid-interval times. Table 1 summarizes the data
for the 12 intervals in the ten studies.
[FIGURE 1 about here.]
[TABLE 1 about here.]
The prior information about the hazards in study ten is captured by theMAP prior. The respective prior for survival (median
and 95%-intervals in right panel of Figure 1 ) shows a median of approximately 1.8 years (95% interval 0.9 to 2.7 years). The
prior effective number of events (Section 2.3) is 58. Figure 1 shows the KM plots of nine historical data (left panel) and MAP
prior (right panel). The KM curve of the tenth trial (thick solid line in the right panel) is also shown in Figure 1.
After having access to the data from trial 10, for illustration we will compare twoMAC analyses and the stratified analysis:
(i) EX: full exchangeabilityMAC analysis. This is model (5) with between-trial standard deviations 휏푘 following half-normal
priors with scale 0.5, which cover small to large heterogeneity (95% interval (0.02,1.12)). For 휂1, unit-information prior
푁(−1.171, 1), centered at log(0.31) (the overall estimated log-hazard for death), is used. 푁(0, 1) priors are used for 휌푖,
푖 = 1… 푘.
(ii) EXNEX: exchangeability-nonexchangeabilityMAC analysis. This is the robust analysis of Section 2.5, where for the tenth
trials we assume weight 0.5 for exchangeability EX (5) and 0.5 for nonexchangeability (NEX) (13). For remaining nine
trials full exchangeability is assumed (weight=1). For EX, the prior assumptions in (i) are used, whereas for NEX the
priors are weakly-informative with means centered at the mean of the MAP prior and variances approximately worth one
observation.
(iii) STRAT: this is the analysis of the data from the tenth study only, ignoring the data from the historical trials. For 휂1, a
non-informative prior푁(0, 102) is used. Similar to EX model,푁(0, 1) priors are used for 휌푖, 푖 = 1… 푘.
For the three analyses, the posterior summaries for yearly survival rates in trial ten are summarized in Table 2. The EX analysis
provides smaller survival rates compared to the stratified analysis, and median survival is 2.01 years, considerably different from
the observed median (2.7 years). On the other hand, the EXNEX analysis is more robust, with a median survival of 2.59 months.
[FIGURE 2 about here.]
[TABLE 2 about here.]
3.2 Study design with historical data
The second application is concerned with the design of a randomized phase II trial for lung cancer with historical control data.
As of 2018, lung cancer is the most common cause of cancer-related death in men and women, responsible for 1.76 million
deaths annually worldwide ( WHO Cancer Factsheet 2018? ).
The aim of the phase II proof-of-concept (POC) study was to compare a new treatment (T) against an active control treatment
(C) for patients with locally advanced recurrent or metastatic lung cancer. The primary endpoint was progression-free survival
(PFS), defined as the time from treatment assignment to disease progression or death from any cause. Superiority of the treatment
T is typically established by a statistically significant log-rank test or an upper confidence limit of the Cox proportional hazard-
ratio (HR) less than 1.
For the control treatment, the median PFS for this population is approximately five months. Assuming a 45% reduction in
PFS (퐻푅 = 0.55) for the new treatment, a 2:1 (T:C) randomization, an enrollment rate of 30 patients per month, a one-sided
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2.5% level of significance and 90% power, the study would require 133 events (230 patients). Due to limited resources, however,
it was decided to leverage historical data and enroll only 130 patients. For this modified design, the final analysis was planned
after 110 events.
After an extensive search, seven historical studies with data for the active control were identified by the clinical team and
disease area experts. Only Kaplan-Meier plots were available from the literature. Figure 3 shows the Kaplan-Meier plots as well
as the number of events and exposure time for the following intervals (in days): (0-30], (30-60], (60-90], (90-120], (120-150],
(150-180], (180-240], (240-300], and (300-360]. The data extraction from the Kaplan-Meier plots was done by the method of
similar to Parmar et al.? ( for details see Appendix A). The Figure 3 shows the rather heterogeneous historical studies (medians
vary between 3.5 months to 6 months) and the MAP prior (median= 4.88 months; 95% interval (1.6 months, 6.2 months)). The
prior effective number of events (Section 2.3) is 36.
[FIGURE 3 about here.]
The frequentist operating characteristics (type-I error, power, bias, and root-mean-square error of the log-hazard ratio) of the
design were assessed for exponential data, two scenarios for the HR (1 and 0.5), and various scenarios for the control median (3.5,
4.5, 5, 5.5, 6.5, and 7.5 months). Study success was defined by the Bayesian criterion 푃 (HR < 1|data) > 0.975 or equivalently
푃 (훽 < 0|data) > 0.975. For 2000 simulated trials, the above metrics were assessed for four models:
(i) EX: full exchangeabilityMAC analysis. This is model (5) with between-trial standard deviations 휏푘 following half-normal
priors with scale 0.5, which cover small to large heterogeneity (95% interval (0.02,1.12)). For 휂1, a unit-information prior
푁(−5.167, 1), centered at log(0.00575) (the overall estimated log-hazard for death), was used. 푁(0, 1) priors were used
for 휌푖, 푖 = 1… 푘.
(ii) EXNEX90: exchangeability-nonexchangeabilityMAC analysis. This is the robust analysis, with weights 0.9 for exchange-
ability EX (5) and 0.1 for nonexchangeability (NEX) (13). For EX, the prior assumptions in (i) were used, whereas for
NEX the priors were assumed as weakly-informative with means centered at the mean of the MAP prior and variances
equals 1 (worth one observation).
(iii) EXNEX50: same as EXNEX90 but with 50-50 weights for exchangeability and nonexchangeability.
(iv) STRAT: the analysis of the data from the new study only, ignoring the data from the historical trials and assuming푁(0, 102)
priors for the log-hazards in each interval.
[TABLE 3 about here.]
Table and Figure 4 summarize the operating characteristics for the four models.Table shows the type-I error and power for
different scenarios. For the type-I error (HR=1), EX and EXNEX90 show fairly similar results. If the assumed control median
is considerably smaller (3.5 months) than the one from the MAP prior (≈ 5 months, Figure 3), the type-I error is much smaller
than 2.5%. On the other hand, if the control median is much larger (6.5 or 7.5 months), the type-I error is larger than 10%. For
the more robust EXNEX50model, however, the type-I error is much less affected. Finally, for the Bayesian stratified analysis, the
type-I error is close to the expected 2.5%. For power (HR=0.55), the analyses that leverage the historical data exhibit substantial
gains compared to the stratified analyses, and power gains increase with increasing true control medians.
The bias on the log-HR scale (left panel of Figure 4) increases with increased leveraging (from stratified to fully exchangeable)
and true control mediansmuch smaller (3.5months) or much larger (7.5months) than suggested by the historical data (5months).
For the non-robust EX model, the bias is approximately –20% for the worst case scenario (true control median 6.5 months) but is
generally much smaller for the robust analyses and true control medians closer to the expected 5 months.The root-mean-square
error (on log-HR scale) (Figure 4) shows gain in efficiency in EX, EXNEX50, EXNEX90 when the new trial data are aligned
with historical data.
[FIGURE 4 about here.]
4 DISCUSSION
Clinical trials results are usually interpreted in the context of other relevant data. In addition to such informal considerations
of historical data, or more generally co-data (Neuenschwander et al.? ), we have considered leveraging historical data in the
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Bayesian analysis of a new clinical trial with a time-to-event endpoint. Historical control data are increasingly used in earlier
stages of drug development. As these studies primarily inform company-internal decisions, the advantages are often consid-
ered to outweigh potential risks. In phase III clinical trials, however, historical controls are currently rare. Yet the regulatory
environment is evolving in special areas such as rare diseases, pediatric populations, and non-inferiority trials (EMEA? ? ? ).
Leveraging historical control data has advantages. First, and most importantly, it allows randomizing fewer patients to the
control group. This will shorten the duration of a clinical trial and hence lead to faster decisions. It will also decrease trial costs,
as fewer patients will be needed. Second, if the control is ineffective (e.g., for placebo), historical data designs may also be more
ethical because fewer patients receive the ineffective treatment (Berry? ).
The selection of historical data requires care and should follow recommendations for systematic reviews. This minimizes
the risk of systematic biases, which can arise as a result of, for example, changes in standard of care over time, differences
in inclusion/exclusion criteria, confounding environmental factors, or the evolution of diagnostic tools. The robust mixture
approach proposed here mitigates some of these problems but cannot compensate for using biased data.
When analyzing the data of the new trial, a suitable model that allows for different degrees of similarity between historical and
new data, is needed. Hierarchical models are the most obvious choice. For piecewise exponential time-to-event data, we have
discussed a flexible model with interval-specific exchangeable hazard parameters and between-trial standard deviations. For few
trials, which is typical for most settings, information on between-trial variability will usually be sparse. Yet valuable information
may be available from similar disease settings, which may lead to more informative prior distributions for the between-trial
standard deviations (Turner et al.? ? ). In the applications of Section 3, due to lack of additional information, we have used prior
distributions that cover the range of small to large heterogeneity.
Widening the scope to real-world evidence, leveragingmore but possibly less relevant data may be of interest. This will require
adjustments to the methodology of Section 2 with regard to bias and heterogeneity. Having access to relevant predictors that
explain anticipated biases will be key, and including these predictors (via meta-regression or propensity score methods) will be
needed. Moreover, if historical data are of different quality, this may be accounted for by using different between-trial standard
deviations. Further research will be needed to incorporate such extensions in the time-to-event setting.
APPENDIX A: EXTRACTION OF DATA FROM PUBLISHED KAPLAN-MEIER PLOTS
For the seven historical trials in Application 2 (NSCLC example),we could only get the Kaplan-Meier plots from the published
articles. The data extraction (number of ... ) was done using the following steps:
1. The time axis is divided into intervals of 30 days up-to 180 days and 60 days afterwards. Based on historical data the
maximum follow up time is restricted to 360 days.
2. Probabilities of remaining progression-free at pre-specified time points are extracted using Engauge Digitizer? , a freeware
that converts an image to numbers.
3. The number of patients at risk in a specific interval is calculated by multiplying the total number of patients with the
probability of remaining progression-free at the beginning of the interval.
4. The number of events (progression or death) within a time interval are approximated by using the probabilities of
remaining progression-free in the current and next interval as follows;
log( ̂푆(푡푖+1)) − log( ̂푆(푡푖)) = 1 −
푑푖
푛푖
where 푑푖 is the number of events and 푛푖 is the risk set for interval [푡푖, 푡푖+1)
5. The exposure time for an interval is the interval length if the patient did not have an event or was not censored. Otherwise,
the exposure of the patient is half the interval length. The total exposure time for an interval is the sum of the individual
exposure times at the risk set.
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APPENDIX B: WINBUGS CODE FOR MAC ANALYSIS
B.1 Main WinBUGS Code
##Required R packages
library(MASS)
library(coda)
library(R2WinBUGS)
library(survival)
library(RBesT)
##Main WinBUGS code
MAC.Surv.WB <- function()
{
# tau.study: Between study variation (Half normal)
Prior.tau.study.prec <- pow(Prior.tau.study[2],-2)
for ( t in 1:Nint) {
tau.study[t] ~ dnorm(Prior.tau.study[1], Prior.tau.study.prec) %_% I(0, )
tau.study.prec[t] <- pow(tau.study[t],-2)
}
#tau.time: correlation for piecewise exponential pieces (log-normal)
Prior.tau.time.prec <- pow(Prior.tau.time[2],-2)
tau.time ~ dlnorm(Prior.tau.time[1], Prior.tau.time.prec)
tau.time.prec <- pow(tau.time,-2)
# priors for regression parameter: h covariates
for (h in 1:Ncov) {
prior.beta.prec[h] <- pow(Prior.beta[2,h],-2)
beta[h,1] ~ dnorm(Prior.beta[1,h],prior.beta.prec[h])
}
###########################
#EXNEX structure of mu
###########################
#EX structure for mu is 1st order NDLM
mu.prec.ex <- pow(Prior.mu.mean.ex[2],-2)
mu.mean.ex ~ dnorm(Prior.mu.mean.ex[1],mu.prec.ex)
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mu1.ex ~ dnorm(mu.mean.ex,tau.time.prec)
mu.ex[1] <- mu1.ex
prec.rho.ex <- pow(Prior.rho.ex[2],-2)
for(t in 2:Nint){
mu.dlm.ex[t] <- mu.ex[t-1] + rho.ex[t-1]
#variance of mu: discount factor X tau.time.prec
mu.time.prec.ex[t] <- tau.time.prec/w.ex
mu.ex[t] ~ dnorm(mu.dlm.ex[t], mu.time.prec.ex[t])
rho.ex[t-1] ~ dnorm(Prior.rho.ex[1], prec.rho.ex)
}
w.ex ~dunif(w1,w2)
#NEX structure for mu: unrelated structure
for( s in 1:Nstudies){
for(t in 1:Nint) {
prior.mu.prec.nex[s,t] <- pow(prior.mu.sd.nex[s,t],-2)
mu.nex[s,t] ~ dnorm(prior.mu.mean.nex[s,t],prior.mu.prec.nex[s,t])
}
}
# hazard-base: for each study (+ population mean + prediction) and time-interval t, no covariates
for ( s in 1:Nstudies) {
for ( t in 1:Nint) {
RE[s,t] ~ dnorm(0,tau.study.prec[t])
Z[s,t] ~ dbin(p.exch[s,t],1)
#For ex
log.hazard.base.ex[s,t] <- mu.ex[t] + step(Nstudies-1.5)*RE[s,t]
#For Nexch
log.hazard.base.nex[s,t] <- mu.nex[s,t]
log.hazard.base[s,t] <- Z[s,t]*log.hazard.base.ex[s,t]+(1-Z[s,t])*log.hazard.base.nex[s,t]
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hazard.base[s,t] <- exp(log.hazard.base[s,t])
}
}
# likelihood: pick hazards according to study and time-invervals (int.low to int.high) for each
#observation j
# note: hazard is per unit time, not depending on length of interval t
for(j in 1:Nobs) {
for ( t in 1:Nint) {
# log.hazard for all time intervals
log(hazard.obs[j,t]) <- log.hazard.base[study[j],t] + inprod(X[j,1:Ncov],beta[1:Ncov,1])
}
#Poisson likelihood
alpha[j] <- (inprod(hazard.obs[j,int.low[j]:int.high[j]],int.length[int.low[j]:int.high[j]])
/sum(int.length[int.low[j]:int.high[j]]))*exp.time[j]
n.events[j] ~ dpois(alpha[j])
n.events.pred[j] ~ dpois(alpha[j])
}
# outputs of interest (from covariate patterns in Xout)
for ( h in 1:Nout) {
for ( s in 1:Nstudies) {
# mean (index = Nstudies)
# surv: pattern x study x time
surv1[ h,s,1] <- 1
for ( t in 1:Nint) {
log(hazard[h,s,t]) <- log.hazard.base[s,t] + inprod(Xout[h,1:Ncov],beta[1:Ncov,1])
log.hazard[h,s,t] <- log(hazard.base[s,t])
surv1[h,s,t+1] <- surv1[h,s,t]*exp(-hazard[h,s,t]*int.length[t])
surv[h,s,t] <- surv1[h,s,t+1]
}
}
}
######### Prediction##########
for ( h in 1:Nout) {
for ( t in 1:Nint) {
hazard.pred[h,t] <- hazard[h,Nstudies,t]
log.hazard.pred[h,t] <- log(hazard[h,Nstudies,t]+pow(10,-6))
surv.pred[h,t] <- surv[h,Nstudies,t]
}
}
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for (j in 1:Ncov) {
beta.ge.cutoffs[j] <- step(beta[j,1]-beta.cutoffs[j,1])
}
}
B.2 R wrapper function for running the main WinBUGS code
##Description of arguments of the function
#Nobs = Total number of data points
#study = Study indicator
#Nstudies = Number of studies
#Nint = Number of intervals
#Ncov = Number of covariates
#int.low, int.high = Interval indicator
#int.length = Length of interval
#n.events = Number of events at each interval
#exp.time = Exposure time for each interval
#X = Important covariates
#Prior.mu.mean.ex = Mean and standard deviation for normal priors for exchangeability for the first interval
#Prior.rho.ex = Mean and standard deviation for normal priors for random gradient of 1st order NDLM
#w1, w2 = Upper and lower bound for uniform prior of the smoothing factor for 1st order NDLM model for exchangeability
#prior.mu.mean.nex = Mean of normal prior for non-exchangeability
#prior.mu.sd.nex = Standard deviation for normal prior of non-exchangeability
#p.exch = Prior probability of exchangeability
#Prior.beta = Mean and standard deviation for normal priors of regression coefficients
#beta.cutoffs = Cut-off for treatment effect
#Prior.tau.study = Scale parameter of half-normal prior for between trial heterogeneity
#Prior.tau.time = Mean and standard deviation for log-normal prior for variance compoment of 1st order NDLM
#MAP.Prior = If TRUE: derives MAP prior
#pars = Parameters to keep in each MCMC run
#bugs.directory = Directory path where WinBUGS14.exe file resides
#R.seed = Seed to generate initial value in R (requires for reprducibility)
#bugs.seed = WinBUGS seed (requires for reprducibility)
MAC.Surv.anal <- function(Nobs = NULL,
study = NULL,
Nstudies = NULL,
Nint = NULL,
Ncov = 1,
Nout = 1,
int.low = NULL,
int.high = NULL,
int.length = NULL,
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n.events = NULL,
exp.time = NULL,
X = NULL,
Xout = matrix(0,1,1),
Prior.mu.mean.ex = NULL,
Prior.rho.ex = NULL,
w1 = 0,
w2 = 1,
prior.mu.mean.nex = NULL,
prior.mu.sd.nex = NULL,
p.exch = NULL,
Prior.beta = NULL,
beta.cutoffs = NULL,
Prior.tau.study = NULL,
Prior.tau.time = NULL,
MAP.prior = FALSE,
pars = c("tau.study","log.hazard","mu.ex", "hazard"),
bugs.directory = "C:/Users/roychs04/Documents/Folder/Software/WinBUGS14",
R.seed = 10,
bugs.seed = 12
)
{
set.seed(R.seed)
beta.cutoffs <- cbind(NULL,beta.cutoffs)
if(MAP.prior){Nstudies <- Nstudies+1}
#WinBUGS model
model <- MAC.Surv.WB
#Data for JAGS format
data = list("Nstudies", "Nint", "Ncov", "Nobs", "Nout","study","int.low","int.high","int.length",
"n.events","exp.time",
"X","Xout",
"Prior.mu.mean.ex","Prior.rho.ex",
"prior.mu.mean.nex","prior.mu.sd.nex",
"p.exch","w1","w2",
"Prior.beta",
"beta.cutoffs",
"Prior.tau.study","Prior.tau.time"
)
#Initial values
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hazard0 = (sum(n.events)+0.5)/sum(exp.time)
initsfun = function(i)
list(
mu1.ex = rnorm(1,log(hazard0),0.25),
tau.study = rgamma(12,1,1),
tau.time = rgamma(1,1,1),
mu.mean.ex = rnorm(1,log(hazard0),0.1),
rho.ex = rnorm(Nint-1,0,0.05),
w.ex = runif(1,0,1),
beta=cbind(NULL,rnorm(Ncov,0,1))
)
inits <- lapply(rep(1,3),initsfun)
#WinBUGS run
fit = bugs(
data=data,
inits=inits,
par=pars,
model=model,
n.chains=3,n.burnin=8000,n.iter=16000,n.thin=1,
bugs.directory= bugs.directory,
bugs.seed= bugs.seed,
DIC= TRUE,
debug= FALSE
)
fit$sims.matrix = NULL
fit$sims.array = NULL
#WinBUGS summary
summary <- fit$summary
R2WB <- fit
output <- list(summary=summary,R2WB =R2WB)
return(output)
}
B.3 FIOCCO Analysis
##FIOCCO data set
14 Roychoudhury ET AL
FIOCCO.n.events <- c(1, 3, 3, 4, 3, 0, 0, 2, 0, 6, 0, 0, 9, 1, 0, 10, 6, 6, 5, 9,
9, 3, 0, 0, 1, 3, 5, 7, 9, 4, 5, 10, 0, 0, 3, 7, 1, 2, 2, 4,
3, 1, 3, 0, 0, 0, 0, 0, 5, 3, 6, 2, 3, 3, 0, 2, 1, 1, 1, 0,
0, 6, 3, 12, 8, 2, 3, 2, 11, 1, 0, 10, 2, 2, 5, 3, 3, 3, 2, 3,
3, 0, 0, 0, 0, 1, 3, 4, 1, 1, 4, 1, 6, 0, 0, 0, 2, 0, 3, 1,
4, 0, 1, 1, 0, 0, 0, 0, 1, 5, 17, 0, 2, 7, 8, 4, 0, 6, 2, 0)
FIOCCO.exp.time <- c( 9.4, 8.8, 7.9, 7.0, 6.1, 5.8, 5.8, 7.3, 8.8, 7.6, 6.2, 10.0, 21.1,
19.9, 19.8, 18.5, 16.5, 15.0, 13.6, 15.7, 16.2, 13.6, 12.5, 20.1, 21.9, 21.4,
20.4, 18.9, 16.9, 15.2, 14.1, 16.2, 18.5, 18.3, 17.0, 24.5, 5.6, 5.2, 4.8,
4.0, 3.1, 2.6, 2.1, 2.3, 2.9, 2.9, 2.9, 4.7, 6.4, 5.4, 4.2, 3.2,
2.6, 1.9, 1.5, 1.7, 1.5, 1.0, 0.6, 0.7, 17.8, 17.0, 15.9, 14.0, 11.5,
10.2, 9.6, 11.9, 12.4, 9.9, 9.4, 12.1, 8.0, 7.5, 6.6, 5.6, 4.9, 4.1,
3.5, 3.8, 3.6, 2.9, 2.9, 4.7, 9.2, 9.1, 8.6, 7.8, 7.1, 6.9, 6.2,
7.4, 8.0, 6.7, 6.6, 10.7, 5.2, 5.0, 4.6, 4.1, 3.5, 3.0, 2.9, 3.5,
4.2, 4.2, 4.1, 6.7, 23.4, 22.6, 19.9, 17.8, 17.5, 16.4, 14.5, 17.2, 21.0,
19.7, 17.4, 27.5)
B.3.1 Derivation of MAP Prior using First 9 Studies
FIOCCO.MAP.Prior <- MAC.Surv.anal(Nobs = 108,
study = sort(rep(1:9,12)),
Nstudies = 9,
Nint = 12,
Ncov = 1,
Nout = 1,
int.low = rep(1:12,9),
int.high = rep(1:12,9),
int.length = c(0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25,
0.33, 0.42, 0.42, 0.41, 0.67),
n.events = FIOCCO.n.events[1:108],
exp.time = FIOCCO.exp.time[1:108],
X = matrix(0,108,1),
Prior.mu.mean.ex = c(0, 10),
Prior.rho.ex = c(0,10),
prior.mu.mean.nex = matrix(rep(0,108), nrow=9, ncol=12),
prior.mu.sd.nex = matrix(rep(1,108), nrow=9, ncol=12),
p.exch = matrix(rep(1,108), nrow=9),
Prior.beta = matrix(c(0,10), nrow=2) ,
beta.cutoffs = 0,
Prior.tau.study = c(0, 0.5),
Prior.tau.time = c(-1.386294, 0.707293),
MAP.prior = TRUE,
pars = c("tau.study","log.hazard.pred"),
R.seed = 10,
bugs.seed = 12
)
print(FIOCCO.MAP.Prior$summary)
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#Calculation of ENE
FIOCCO.MAP.ess <- NULL
for(l in 1:12){
prior.ss.int <- FIOCCO.MAP.Prior$R2WB$sims.list$log.hazard.pred[,,l]
prior.ss.int.mix <- RBesT::automixfit(prior.ss.int, type="norm")
FIOCCO.MAP.ess[l] <- RBesT::ess(prior.ss.int.mix, sigma=1)
}
#Prior ESS (mixture)
FIOCCO.ESS.nevent <- sum(FIOCCO.MAP.ess)
B.3.1 MAC analysis of FIOCCO data
FIOCCO.anal.1 <- MAC.Surv.anal(Nobs = 120,
study = sort(rep(1:10,12)),
Nstudies = 10,
Nint = 12,
Ncov = 1,
Nout = 1,
int.low = rep(1:12,10),
int.high = rep(1:12,10),
int.length = c(0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25,
0.33, 0.42, 0.42, 0.41, 0.67),
n.events = FIOCCO.n.events,
exp.time = FIOCCO.exp.time,
X = matrix(0,120,1),
Prior.mu.mean.ex = c(-1.1711, 1),
Prior.rho.ex = c(0,1),
prior.mu.mean.nex = matrix(rep(0,120), nrow=10, ncol=12),
prior.mu.sd.nex = matrix(rep(1,120), nrow=10, ncol=12),
p.exch = matrix(rep(1,120), nrow=10),
Prior.beta = matrix(c(0,10), nrow=2) ,
beta.cutoffs = 0,
Prior.tau.study = c(0, 0.5),
Prior.tau.time = c(-1.386294, 0.707293),
R.seed = 10,
bugs.seed = 12
)
print(FIOCCO.anal.1$summary)
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B.3.2 Robust MAC analysis of FIOCCO data
FIOCCO.anal.2 <- MAC.Surv.anal(Nobs = 120,
study = sort(rep(1:10,12)),
Nstudies = 10,
Nint = 12,
Ncov = 1,
Nout = 1,
int.low = rep(1:12,10),
int.high = rep(1:12,10),
int.length = c(0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.33,
0.42, 0.42, 0.41, 0.67),
n.events = FIOCCO.n.events,
exp.time = FIOCCO.exp.time,
X = matrix(0,120,1),
Prior.mu.mean.ex = c(-1.1711, 1),
Prior.rho.ex = c(0,1),
prior.mu.mean.nex = matrix(rep(c(-1.8625303, -1.6057708, -1.1242566,
-0.5940037, -0.5921193, -1.2484085,
-1.0011891, -0.9291769, -1.3337843,
-2.1254918, -2.9740698, -2.7570149),
10),
nrow=10, byrow = T),
prior.mu.sd.nex = matrix(rep(1,12*10), nrow=10, byrow=T),
p.exch = rbind(matrix(rep(1,108), nrow=9), rep(0.5, 12)),
Prior.beta = matrix(c(0,10), nrow=2) ,
beta.cutoffs = 0,
Prior.tau.study = c(0, 0.5),
Prior.tau.time = c(-1.386294, 0.707293),
R.seed = 10,
bugs.seed = 12
)
print(FIOCCO.anal.2$summary)
References
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predictive (MAP) prior (median (solid line), 95%-interval (dashed line) in right panel), and Kaplan-Meier curve for new data
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TABLE 1 Application 1: number of deaths/exposure time for 12 intervals in ten studies
historical studies
interval 1 2 3 4 5 6 7 8 9 new study
(years)
0.00-0.25 1/9.4 9/21.1 1/21.9 1/5.6 5/6.4 0/17.8 2/8.0 0/9.2 2/5.2 1/23.4
0.25-0.50 3/8.8 1/19.9 3/21.4 2/5.2 3/5.4 6/17.0 2/7.5 1/9.1 0/5.0 5/22.6
0.50-0.75 3/7.9 0/19.8 5/20.4 2/4.8 6/4.2 3/15.9 5/6.6 3/8.6 3/4.6 17/19.9
0.75-1.00 4/7.0 10/18.5 7/18.9 4/4.0 2/3.2 12/14.0 3/5.6 4/7.8 1/4.1 0/17.8
1.00-1.25 3/6.1 6/16.5 9/16.9 3/3.1 3/2.6 8/11.5 3/4.9 1/7.1 4/3.5 2/17.5
1.25-1.50 0/5.8 6/15.0 4/15.2 1/2.6 3/1.9 2/10.2 3/4.1 1/6.9 0/3.0 7/16.4
1.50-1.75 0/5.8 5/13.6 5/14.1 3/2.1 0/1.5 3/9.6 2/3.5 4/6.2 1/2.9 8/14.5
1.75-2.08 2/7.3 9/15.7 10/16.2 0/2.3 2/1.7 2/11.9 3/3.8 1/7.4 1/3.5 4/17.2
2.08-2.50 0/8.8 9/16.2 0/18.5 0/2.9 1/1.5 11/12.4 3/3.6 6/8.0 0/4.2 0/21.0
2.50-2.92 6/7.6 3/13.6 0/18.3 0/2.9 1/1.0 1/9.9 0/2.9 0/6.7 0/4.2 6/19.7
2.92-3.33 0/6.2 0/12.5 3/17.0 0/2.9 1/0.6 0/9.4 0/2.9 0/6.6 0/4.1 2/17.4
3.33-4.00 0/10.0 0/20.1 7/24.5 0/4.7 0/0.7 10/12.1 0/4.7 0/10.7 0/6.7 0/27.5
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TABLE 2Application 1: posterior median (95%-interval) for yearly survival rates and median survival, and two approximations
of the posterior effective number of events (ENE) for exchangeability, exchangeability-nonexchangeability, and stratified analysis
EX EXNEX STRAT
survival rate
1 year 0.72 (0.57, 0.86) 0.74 (0.59, 0.86) 0.75 (0.60, 0.87)
2 year 0.50 (0.31, 0.71) 0.53 (0.31, 0.75) 0.54 (0.32, 0.77)
3 year 0.43 (0.22, 0.67) 0.45 (0.22, 0.71) 0.47 (0.23, 0.73)
4 year 0.41 (0.19, 0.67) 0.44 (0.20, 0.71) 0.44 (0.20, 0.71)
median survival (years) 2.24 (1.59, 3.19) 2.62 (1.68, 5.05) 7.90 (1.69, 39.86)
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TABLE 3 Application 2: type-I error and power (%) for different control medians (3.5 to 7.5 months) and treatment effects
(hazard ratio = 1 or 0.55) for EX, EXNEX90, EXNEX50, and STRAT analysis
scenarios control treatment EX EXNEX90 EXNEX50 STRAT
median median
HR=1 (type-I error)
1 3.5 3.5 < 0.01 < 0.01 < 0.01 2.6
2 4.5 4.5 3.7 2.7 2.1 2.5
3 5.0 5.0 5.3 5.1 4.0 2.5
4 5.5 5.5 9.0 8.3 5.9 2.8
5 6.5 6.5 16.3 14.5 9.4 2.7
6 7.5 7.5 23.7 20.9 13.2 2.6
HR=0.55 (power)
7 3.5 6.4 91.7 90.9 88.6 85.2
8 4.5 8.2 97.3 96.9 94.5 84.9
9 5.0 9.1 97.0 96.8 96.1 84.6
10 5.5 10.0 98.9 98.7 97.1 85.0
11 6.5 11.8 99.3 99.2 98.0 84.8
12 7.5 13.6 99.7 99.5 98.5 84.5
